...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>British Journal of Haematology >The future role of monoclonal antibody therapy in childhood acute leukaemias
【24h】

The future role of monoclonal antibody therapy in childhood acute leukaemias

机译：单克隆抗体治疗在儿童急性白血病中的未来作用

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Leukaemia is the single most common childhood malignancy. With modern treatment regimens, survival in acute lymphoblastic leukaemia (ALL) approaches 90%. Only about 70% of children with acute myeloid leukaemia (AML) achieve long term survival. Patients who relapse have a dismal prognosis. Novel therapeutic approaches are needed to improve treatment outcomes in newly-diagnosed patients with a poor prognosis and for patients with relapsed/refractory disease that have limited treatment options. One promising approach in treating haematological malignancies has been the use of monoclonal antibodies to target cell surface antigens expressed on malignant cells. Most success with monoclonal antibody therapy in the treatment of haematological malignancies has come in the setting of adult B-cell non-Hodgkin lymphoma with the addition of the anti-CD20 monoclonal antibody rituximab to standard treatment regimens. In order to further advance treatment of haematological malignancies, novel monoclonal antibodies continue to be developed that target a variety of cell surface antigens. Several antibodies continue to be investigated in childhood leukaemias. This review will discuss the development of monoclonal antibodies that target a variety of cell surface antigens for the treatment of childhood ALL and the use of the anti-CD33 antibody gemtuzumab ozogamicin in the treatment of childhood AML.
机译：白血病是最常见的儿童恶性肿瘤。采用现代治疗方案，急性淋巴细胞白血病（ALL）的存活率接近90％。仅有约70％的急性髓细胞性白血病（AML）儿童可以长期生存。复发的患者预后不良。需要新的治疗方法来改善新诊断的预后差的患者以及治疗选择有限的复发/难治性疾病患者的治疗效果。治疗血液系统恶性肿瘤的一种有前途的方法是使用单克隆抗体靶向在恶性细胞上表达的细胞表面抗原。单克隆抗体疗法在血液系统恶性肿瘤治疗中的最成功成就是在成人B细胞非霍奇金淋巴瘤的治疗中，在标准治疗方案中添加了抗CD20单克隆抗体利妥昔单抗。为了进一步推进血液系统恶性肿瘤的治疗，继续开发靶向多种细胞表面抗原的新型单克隆抗体。在儿童白血病中继续研究几种抗体。这篇综述将讨论针对多种细胞表面抗原的单克隆抗体的开发，以治疗儿童ALL，以及抗CD33抗体吉妥珠单抗ozogamicin在儿童AML中的应用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号